Revised consolidated earnings forecast for the fiscal year ending December 2026. Revenue is forecast at 48,800 million yen, core operating profit at 22,800 million yen, and operating income at 15,700 million yen. Assumes receipt of a $100 million USD upfront payment, recognized as revenue. Previous upper-bound forecast has been adjusted to a specific value; foreign exchange assumption is 1 USD = 157.8 yen. Completion of the transaction and auditor agreement are conditions precedent.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nxera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4565-20261104-01.pdf","jir_short_summary":"Revised consolidated earnings forecast for the fiscal year ending December 2026. Revenue is forecast at 48,800 million yen, core operating profit at 22,800 million yen, and operating income at 15,700 million yen. Assumes receipt of a $100 million USD upfront payment, recognized as revenue. Previous upper-bound forecast has been adjusted to a specific value; foreign exchange assumption is 1 USD = 157.8 yen. Completion of the transaction and auditor agreement are conditions precedent.","jir_summary":"### Revision of Earnings Forecast and Background\nThe revised consolidated earnings forecast for the fiscal year ending December 2026 published today assumes receipt of a $100 million USD upfront payment under an exclusive license agreement between subsidiary Nxera Pharma UK Ltd and AbbVie Inc. The foreign exchange assumption is 1 USD = 157.8 yen. Revenue is expected to be 48,800 million yen, core operating profit 22,800 million yen, and operating income 15,700 million yen, with the previous upper bound revised to a specific value. The revision is subject to completion of the transaction and agreement with the auditor; if completion is delayed or the assumptions change, we will disclose updates.\n\n### Impact on Business Strategy and Outlook\nThrough partnerships leveraging Nxera Pharma\u2019s pipeline, including its EP4 agonist program, we intend to expand global revenue opportunities. The accounting treatment for the upfront payment will be to recognize it as revenue in the fourth quarter of the fiscal year ending December 2026, which is expected to contribute to future business revenue growth. However, if the transaction conditions are not met or the foreign exchange assumptions change, we may revise the earnings forecast again.","jir_financial_highlights":"Revenue: 48,800 (Adjusted to a specific value instead of following the upper bound of the prior Forecast A)\nCore Operating Profit: 22,800 (Same amount as prior Forecast A)\nOperating Income: 15,700 (Same amount as prior Forecast A)","jir_category":"","jir_hashtags":"#NxeraPharma, #EarningsRevision","jir_key_figures":"Revenue: 48,800 million yen\nCore Operating Profit: 22,800 million yen\nOperating Income: 15,700 million yen","jir_meta_title":"Nxera Pharma Co., Ltd. \u2014 Revision to Earnings Forecast for Fiscal Year Ending December 2026 | Revenue 48,800 million yen, Operating Income 15,700 million yen","jir_meta_description":"Nxera Pharma Co., Ltd. has revised its earnings forecast for the fiscal year ending December 2026. Assuming recognition of a $100 million USD upfront payment, revenue is projected at 48,800 million yen, core operating profit at 22,800 million yen, and operating income at 15,700 million yen. Completion conditions and FX assumptions are specified.","jir_og_title":"Nxera Pharma Co., Ltd. Announces Revision to Earnings Forecast | Revenue 48,800 million yen","jir_og_description":"Nxera Pharma Co., Ltd. has revised its earnings forecast for the fiscal year ending December 2026, updating key metrics on the assumption that an upfront payment will be recognized as revenue.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141152","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n